For years, the PBM industry has fostered misalignment, opacity, and consolidation. Rather than improving drug value and creating an efficient marketplace, the industry has fueled a flawed maze model that impairs competition to the detriment of employers/purchasers and consumers. Seasoned advisors will offer guidance to enable attendees to break through the intentional dead ends set forth by yesterday’s PBMs. The view of the “Big 3” PBMs will start the conversation, followed by a reactor panel of PBM professionals weighing in on what they are doing to ensure transparency and answer questions about how they are putting employers and working families first.